Study summary · research use only
Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity
Plain-language summary
Paraphrased from the published abstract below — not a verdict on whether anything works.
This review article (species not specified) discusses new and emerging medications and treatment regimens for diabetes and obesity, describing diabetes as closely linked to obesity and noting that current therapeutics have not fully met ongoing needs. The authors describe promising results in advanced clinical trials for new therapies, including teplizumab, ustekinumab, JAK inhibitors, and cell therapies for type 1 diabetes, and once-weekly insulin, tirzepatide, high oral dose semaglutide, orforglipron, retatrutide, CagriSema, and survodutide for type 2 diabetes. The authors describe these medications and regimens as structurally and mechanistically diverse, and as potentially enabling improved disease prevention and management, providing an overview of each strategy.
Abstract
Diabetes is a chronic illness that can become debilitating owing to its microvascular and macrovascular complications. Its prevalence is increasing and so is its cost. Diabetes, particularly type 2, appears to have a very close relationship with obesity. While lifestyle modifications, exercises, and current therapeutics have substantially improved clinical outcomes, the need for new therapeutics and regimens continue to exist. Several new medications and regimens for diabetes, obesity, and diabesity are showing promising results in advanced clinical trials. For type 1 diabetes mellitus (T1DM), they include teplizumab, ustekinumab, jakinibs, and cell therapies, whereas for type 2 diabetes mellitus (T2DM), they include once-weakly insulin, tirzepatide, high oral dose of semaglutide, orforglipron, retatrutide, CagriSema, and survodutide. Given their structural and mechanistic diversity as well as their substantial efficacy and safety profiles, these medications and regimens are paradigm shifting and promise a brighter future. They will likely enable better disease prevention and management. This review will provide details about each of the above strategies to keep the scientific community up to date about progress in the fields of diabetes and obesity.
pepmg summarizes the peer-reviewed literature and links to every source — it sells nothing, ships nothing, and gives no medical, dosing, or human-use guidance. Don't just trust this summary: follow the citation to its source and read it yourself. Research use only.